口腔黏膜下纤维性变病损黏膜下曲安奈德联合丹参酮液注射方法及疗效探讨

doi:10.19439/j.sjos.2017.02.013

上海口腔医学 ›› 2017, Vol. 26 ›› Issue (2): 188-192.doi: 10.19439/j.sjos.2017.02.013

口腔黏膜下纤维性变病损黏膜下曲安奈德联合丹参酮液注射方法及疗效探讨

肖益彩¹, 翦新春^2,3, 郑廉², 周超², 杜永秀³, 周婷³, 王彬娉³

1.中南大学湘雅三医院肿瘤科,湖南长沙 410013;
2.中南大学湘雅医院口腔医学中心口腔颌面外科,中南大学口腔癌前病变研究所,湖南长沙 410008;
3.中南大学湘雅医学院附属海口医院口腔医学中心口腔黏膜病科,海南海口 570208

收稿日期:2016-07-28 修回日期:2016-11-01 出版日期:2017-04-25 发布日期:2017-05-04
通讯作者: 翦新春,E-mail：jianxinchun@hotmail.com
作者简介:肖益彩（1973-）,女,硕士, E-mail： 2654538827@qq.com
基金资助:
国家自然科学基金（81041052,30572044）

Methods and effects of injection of salvianolic acid B combined with triamcinolone acetonide in the treatment of oral submucous fibrosis

XIAO Yi-cai¹, JIAN Xin-chun^2,3, ZHENG Lian², ZHOU Chao², DU Yong-xiu³, ZHOU Ting³, WANG Bin-ping³

1.Department of Oncology, the Third Xiangya Hospital, Central South University. Changsha 410013, Hunan Province;
2.Department of Oral and Maxillofacial Surgery, Xiangya Hospital, Central South University. Changsha 410008, Hunan Province;
3.Department of Oral Mucous Disease, Affiliated Haikou Hospital, Xiangya Medical College, Central South University. Haikou 570208, Hainan Province, China

Received:2016-07-28 Revised:2016-11-01 Online:2017-04-25 Published:2017-05-04

摘要/Abstract

摘要： 目的: 评价曲安奈德联合丹参酮注射液口腔黏膜病变下注射治疗口腔黏膜下纤维性变的方法和效果。方法: 对127例口腔黏膜下纤维性变患者,采用曲安德奈联合丹参酮注射液行双侧颊黏膜病变下局部注射。每周注射1次,每10次为1个疗程,每注射10次后间隔30 d,然后进行第2个疗程10次,间隔30 d,再进行第3个疗程的治疗,共注射30次。对临床疗程完成后12、24和36个月的开口度及双侧颊黏膜由灰白变红色面积进行评估,应用SPSS21.0 软件包对数据进行统计学处理。结果: 114例患者完成治疗全过程的疗效观察。早期组治疗3 a后获净开口度（12.0± 1.2）mm,中期组治疗3 a后获净开口度（14.5±2.4）mm,后期组治疗3 a后获净开口度（15.5±1.5）mm。颊黏膜的颜色和血管数量增多的程度,早期组在治疗追踪的第3年结束时,19例患者毛细血管数量增多程度的有效率为100%,中期组为94.7%,后期组为90.7%。结论: 曲安德奈联合丹参酮注射液注射治疗口腔黏膜下纤维性变,对患者开口度、病变黏膜颜色及毛细血管数量的恢复有良好效果。

关键词: 口腔黏膜病, 口腔黏膜下纤维性变, 曲安奈德, 丹参酮

Abstract: PURPOSES: To introduce the methods of triamcinolone acetonide (TA) and salvianolic acid B(SA-B) intralesional injection in the treatment of oral submucous fibrosis and evaluate the treatment effects. METHODS: TA combined with SA-B were consecutively applied intralesionally 1 time weekly for 30 times. The technique of intralesional injection was that syringe needle be emptied into submucous tissues 1 cm posterior to the corner of oral cavity running from the front to retromolar area by pushing the injection, then the syringe needle retained to the original point and upward from the front to retromolar area by pushing the injection, finally the syringe needle returned to the starting point and downward from the front to retromolar area by pushing the injection. Mouth opening, the color change of the buccal mucosa and the increase of capillary vessels as determined by degree I-IV visual analog scale were evaluated at 12, 24, and 36 month. The data were analyzed with SPSS 21.0 software package. RESULTS: One hundred and fourteen subjects fulfilled the study without obvious adverse reactions. After treatment for 36 months , the net gain in mouth opening of the early stage group,middle stage group and advanced stage group was (12.0±1.2) mm, (14.5±2.4) mm and (15.5±1.5) mm, respectively. The response rate of color change of the buccal mucosa and the increase of capillary vessels in early stage group, middle stage group and advanced stage group after treatment for 36 months was 100%, 94.7% and 90.7%, respectively. CONCLUSIONS: Triamcinolone acetonide and salvianolic acid B intralesional injection is effective in the treatment of oral submucous fibrosis.

Key words: Oral mucous disease, Oral submucous fibrosis, Triamcinolone acetonide, Salvianolic acid B

中图分类号:

R781.5

肖益彩, 翦新春, 郑廉, 周超, 杜永秀, 周婷, 王彬娉. 口腔黏膜下纤维性变病损黏膜下曲安奈德联合丹参酮液注射方法及疗效探讨[J]. 上海口腔医学, 2017, 26(2): 188-192.

XIAO Yi-cai, JIAN Xin-chun, ZHENG Lian, ZHOU Chao, DU Yong-xiu, ZHOU Ting, WANG Bin-ping. Methods and effects of injection of salvianolic acid B combined with triamcinolone acetonide in the treatment of oral submucous fibrosis[J]. Shanghai Journal of Stomatology, 2017, 26(2): 188-192.

参考文献

[1] 翦新春, 沈子华, 刘蜀凡. 口腔黏膜下纤维性变（附2例报告）[J]. 临床口腔医学杂志, 1985, 1(1): 12-13.
[2] Tang JG, Jian XF, Gao ML, et al. Epidemiological survey of oral submucous fibrosis in Xiangtan City, Hunan Province, China [J]. Community Dent Oral Epidemiol, 1997, 25(2): 177-180.
[3] Yang YH, Lee HY, Tung S, et al. Epidemiological survey of oral submucous fibrosis and leukoplakia in aborigines of Taiwan [J]. J Oral Pathol Med, 2001, 30(4): 213-219.
[4] Rajendran R. Oral submucous fibrosis: etiology, pathogenesis, and future research [J]. Bull World Health Organ, 1994, 72(6): 985-996.
[5] Liao PH, Lee TL, Yang LC, et al. Adenomatous polyposis coli gene mutation and decreased wild-type p53 protein expression in oral submucous fibrosis: a preliminary investigation [J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2011, 92(2): 202-207.
[6] Ariyawardana A, Athukorala AD, Arulanandam A. Effect of betel chewing, tobacco smoking and alcohol consumption on oral submucous fibrosis: a case-control study in Sri Lanka [J]. J Oral Pathol Med, 2006, 35(4): 197-201.
[7] IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Betel-quid and areca nut chewing and some areca-nut derived nitrosamins [J]. IARC Monogr Eval Carcinog Risks Hum, 2004, 85: 1-334.
[8] 胡延佳, 翦新春, 刘斌杰, 等. 2种基因芯片数据分析软件在口腔黏膜下纤维化差异表达基因分析中的应用[J]. 中华口腔医学杂志, 2008, 43(3): 168-171.
[9] Li N, Jian X, Hu Y, et al. Discovery of novel biomarkers in oral submucous fibrosis by microarray analysis [J]. Cancer Epidemiol Biomarkers Prev, 2008, 17(5): 2249-2259.
[10] 翦新春. 口腔黏膜下纤维性变及癌变机理研究进展（述评）[J]. 中国医师杂志, 2015, 17(9): 1281-1285.
[11] Canniff JP, Harvey W, Harris M. Oral submucous fibrosis: its pathogenesis and management [J]. Br Dent J, 1986, 160(12): 429-434.
[12] Huang IY, Wu CF, Shen YS, et al, Importance of patient's cooperation in surgical treatment for oral submucous fibrosis [J]. J Oral Maxillofac Surg, 2008, 66(4): 699-703.
[13] Liu P, Hu YY, Liu C, et al. Clinical observation of salvianolic acid B in treatment of liver fibrosis in chronic hepatitis B [J]. World J Gastroenterol, 2002, 8(5): 679-685.
[14] 中华口腔医学会口腔黏膜病专业委员会. 口腔黏黏膜下纤维性变的诊断标准（试行稿）[J]. 中华口腔医学杂志, 2009, 44(30): 130-131.
[15] Tilakaratne WM, Klinikowski MF, Saku T, et al. Oral submucous fibrosis: review on aetiology and pathogenesis [J]. Oral Oncol, 2006, 42(6): 561-568.
[16] Rajalalitha P, Vali S. Molecular pathogenesis of oral submucous fibrosis-a collagen metabolic disorder[J]. J Oral Pathol Med, 2005, 34(6): 321-328.
[17] Gupta S, Reddy MV, Harinath BC. Role of oxidative stress and antioxidants in aetiopathogenesis and management of oral submucous fibrosis[J]. Indian J Clin Biochem, 2004, 19(1): 138-141.
[18] Haqueous MF, Harris M, Meghji S, et al. Immunolocalization of cytokines and growth factors in oral submucous fibrosis [J]. Cytokine, 1998, 10(9): 713-719.
[19] Singh M, Niranjan HS, Mehrotra R, et al. Efficacy of hydrocortisone acetate/hyaluronidase vs triamcinolone acetonide/ hyaluronidase in the treatment of oral submucous fibrosis [J]. Indian J Med Res, 2010, 131: 665-669.
[20] Wang X, Morris-Natschke SL, Lee KH. New developments in the chemistry and biology of the bioactive constituents of Tan-shen [J]. Med Res Rev, 2007, 27(1): 133-148.
[21] Li LN. Biologically active components from traditional Chinese medicines [J]. Pure Appl Chem, 2008, 70(3): 547-554.
[22] Liu P, Liu CH, Wang HN, et al. Effect of salvianolic acid B on collagen production and mitogen-activated protein kinase activity in rat hepatic stellate cells[J]. Acta Phamacol Sin, 2001, 23(8): 733-738.
[23] Lv Z, Xu L. Salvianolic acid B inhibits ERK and p38 MAPK Signaling in TGF-B1 stimulated human hepatic stellate cell line (LX-2) via distinct pathways[J]. Evid Based Complement Alternat Med, 2012, 20（2）: 96-128.
[24] Wang SX, Hu LM, Gao XM, et al. Anti-inflammatory activity of salvianolic acid B in microglia contributes to its neuroprotective effect [J]. Neurochem Res, 2010, 35(7): 1029-1037.
[25] Chen T, Liu W, Chao X. et al. Salvianolic acid B attenuates brain damage and inflammtion after traumatic brain injury in mice[J]. Brain Res Bull, 2011, 84(2): 163-168.

口腔黏膜下纤维性变病损黏膜下曲安奈德联合丹参酮液注射方法及疗效探讨

Methods and effects of injection of salvianolic acid B combined with triamcinolone acetonide in the treatment of oral submucous fibrosis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 7

编辑推荐

Metrics

本文评价

[1]	杨一凡, 骆春梅, 李小兵, 杜芹. 温度与辣椒素对大鼠口腔黏膜的刺激效应[J]. 上海口腔医学, 2023, 32(4): 363-368.
[2]	周勇, 周政权, 刘雪威, 张力木, 王也, 林晓萍. 儿童外周血微量营养素与4种口腔黏膜病的关系：217例临床分析[J]. 上海口腔医学, 2022, 31(3): 274-281.
[3]	上海市口腔医学会口腔黏膜病专业委员会, 上海第九人民医院集团口腔黏膜病专科联盟. 新型冠状病毒感染疫情防控阶段口腔黏膜病诊疗的专家建议[J]. 上海口腔医学, 2020, 29(2): 118-122.
[4]	王莉丽, 刘向红, 杨璐铭, 李贤娴. 185例活动义齿患者的义齿相关性口腔黏膜病临床分析[J]. 上海口腔医学, 2020, 29(1): 85-88.
[5]	冯天明, 杨明聪, 潘兰兰, 费晨曦, 王超, 向学熔, 孙珺. 低频超声联合曲安奈德对金黄地鼠颊黏膜溃疡愈合的影响[J]. 上海口腔医学, 2017, 26(4): 379-383.
[6]	朱蓉, 翦新春, 刘德裕, 周超, 王媛. PTPRZ1在口腔黏膜下纤维性变癌变中的表达及临床意义[J]. 上海口腔医学, 2017, 26(2): 198-203.
[7]	黄吉燕, 李含卿, 陈梁, 赵厚明, 周海文. 309例口腔扁平苔藓患者药物依从性与饮食依从性调查分析[J]. 上海口腔医学, 2016, 25(3): 340-344.